OTCMKTS:GSGTF

GenSight Biologics Stock Forecast, Price & News

$9.35
0.00 (0.00 %)
(As of 09/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.35
▼
$9.35
50-Day Range
$6.10
▼
$9.90
52-Week Range
$3.10
▼
$11.30
VolumeN/A
Average Volume1,639 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GSGTF News and Ratings via Email

Sign-up to receive the latest news and ratings for GenSight Biologics and its competitors with MarketBeat's FREE daily newsletter.


GenSight Biologics logo

About GenSight Biologics

GenSight Biologics SA is a clinical-stage gene therapy company. It engages in research and development of novel therapies for mitochondrial and neurodegenerative. The company also provides ophthalmology services which develops products to restore eyesight to patients suffering from retinal diseases. GenSight Biologics was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.

Headlines

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
September 15, 2021 |  finance.yahoo.com
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
September 9, 2021 |  finance.yahoo.com
GenSight Biologics (OTCMKTS:GSGTF) Trading 53.3% Higher
GenSight Biologics (OTCMKTS:GSGTF) Trading 53.3% Higher
September 9, 2021 |  americanbankingnews.com
UK MHRA Grants GenSight Biologics LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
UK MHRA Grants GenSight Biologics' LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
September 6, 2021 |  benzinga.com
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
September 6, 2021 |  finance.yahoo.com
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September
Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September
September 1, 2021 |  finance.yahoo.com
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
August 31, 2021 |  finance.yahoo.com
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update
GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update
July 29, 2021 |  finance.yahoo.com
GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
GenSight Biologics to Host Key Opinion Leader Webcasts on the Topline Results from REFLECT Phase III Clinical Trial of LUMEVOQ®
July 5, 2021 |  finance.yahoo.com
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
July 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GenSight Biologics (OTCMKTS:GSGTF) Frequently Asked Questions

What stocks does MarketBeat like better than GenSight Biologics?

Wall Street analysts have given GenSight Biologics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GenSight Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are GenSight Biologics' key executives?

GenSight Biologics' management team includes the following people:
  • Bernard Jacques Alex Gilly, Chief Executive Officer & Director
  • Laurence Rodriguez, Director-Operations
  • Thomas Gidoin, Chief Financial Officer
  • Magali Taiel, Chief Medical Officer
  • Marion Ghibaudo, Chief Technical Officer

Who are some of GenSight Biologics' key competitors?

Some companies that are related to GenSight Biologics include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of GSGTF's competitors.

What is GenSight Biologics' stock symbol?

GenSight Biologics trades on the OTCMKTS under the ticker symbol "GSGTF."

How do I buy shares of GenSight Biologics?

Shares of GSGTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GenSight Biologics' stock price today?

One share of GSGTF stock can currently be purchased for approximately $9.35.

How many employees does GenSight Biologics have?

GenSight Biologics employs 25 workers across the globe.

What is GenSight Biologics' official website?

The official website for GenSight Biologics is www.gensight-biologics.com.

Where are GenSight Biologics' headquarters?

GenSight Biologics is headquartered at 74, rue du Faubourg Saint-Antoine, Paris, Ile-de-France 75012.


This page was last updated on 9/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.